{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:39Z","timestamp":1790345019438,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 22K20788"],"award-info":[{"award-number":["JP 22K20788"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15577"],"award-info":[{"award-number":["22K15577"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lungcan.2026.109492","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:19:48Z","timestamp":1781021988000},"page":"109492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-5432","authenticated-orcid":false,"given":"Hayato","family":"Koba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-4533","authenticated-orcid":false,"given":"Yuichi","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-357X","authenticated-orcid":false,"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-4859","authenticated-orcid":false,"given":"Hiroki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8356-9849","authenticated-orcid":false,"given":"Shigeki","family":"Nanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lungcan.2026.109492_b0005","first-page":"2594","article-title":"Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib","volume":"24","author":"Liu","year":"2018","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.lungcan.2026.109492_b0010","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109492_b0015","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109492_b0020","article-title":"Acquired ERBB2 amplification and overexpression as on-target resistance mechanisms to zongertinib with subsequent response to trastuzumab-deruxtecan: a case report","volume":"7","author":"McMahon","year":"2026","journal-title":"JTO Clin Res Rep"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109492_b0025","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1158\/2767-9764.CRC-23-0302","article-title":"HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer","volume":"3","author":"Olson","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.lungcan.2026.109492_b0030","doi-asserted-by":"crossref","DOI":"10.1111\/cas.70319","article-title":"Therapeutic strategies to overcome payload resistance of trastuzumab deruxtecan in HER2-positive cancers","author":"Murase","year":"2026","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2026.109492_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.01.007","article-title":"Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs","author":"Nilsson","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109492_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:28:06Z","timestamp":1790342886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":8,"alternative-id":["S0169500226005532"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109492","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109492"}}